Tweenvest Stocks

iTeos Therapeutics, Inc. (NasdaqGM: ITOS)

Health Care · Biotechnology · US

$—

— today · — 1Y

iTeos Therapeutics, Inc. (NasdaqGM: ITOS) operates in the Biotechnology industry within the Health Care sector.

Tweenvest scores iTeos Therapeutics, Inc. across four factors: quality 42/100, value 58/100. Its strongest factor is value.

ITOS price history

Not enough price history to draw a chart yet.

Key figures

Market cap
—
Revenue (TTM)
$0.00
P/E
—
EPS
-4.68
Dividend yield
—
Beta (5Y)
—
52-week high
$—
52-week low
$—
Avg volume (3M)
—
Shares outstanding
—
Employees
173
Next earnings
—

About iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment. Furthermore, EOS-448's mechanism involves engaging the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages, thereby promoting antibody-dependent cellular cytotoxicity (ADCC). Established in 2011, iTeos Therapeutics, Inc. is based in Watertown, Massachusetts.

ISIN
US46565G1040
Founded
2011
Listed since
Jul 24, 2020
Exchange
Nasdaq Global Market
Currency
USD
CompanyMarket capPriceDay
PhaseRx, Inc.OTCPK: PZRX.Q$12.00$——
ContraFect CorporationOTCPK: CFRX.Q$11.00$0.00—
Notable Labs, Ltd.OTCPK: NTBL.Q$10.00$——
OncoSec Medical IncorporatedOTCPK: ONCS.Q$6.00$0.00—
Calithera Biosciences, Inc.OTCPK: CALA$5.00$0.00-99.00%
Biocept, Inc.OTCPK: BIOC.Q$3.00$0.00-99.50%
Yield10 Bioscience, Inc.OTCPK: YTEN.Q$1.00$——
LadRx CorporationOTCPK: LADX$0.00$0.00-99.50%

Browse every Biotechnology company →

Figures last refreshed Oct 18, 2026.